迪哲（江苏）医药股份有限公司 自愿披露关于高瑞哲®和 Birelentinib 最新研究数据 在第 67 届美国临床血液学会（ASH）发布的公告 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 证券代码：688192 证券简称：迪哲医药 公告编号：2025-60 迪哲（江苏）医药股份有限公司（以下简称"公司"）在第 67 届美国临床 血液学会（American Society of Hematology，ASH）大会上，公布了公司自主研 发的两款全球首创新药的最新研究成果：高选择性 JAK1 抑制剂高瑞哲®（通用 名：戈利昔替尼胶囊）在 T 细胞淋巴瘤领域取得多项新进展，以及非共价 LYN/BTK 双靶点抑制剂 birelentinib（DZD8586）在 B 细胞淋巴瘤治疗领域的最 新临床数据。 一、高瑞哲®在 T 细胞淋巴瘤领域的最新进展 1. 外周 T 细胞淋巴瘤（PTCL）一线治疗 在新诊断外周 T 细胞淋巴瘤患者中，高瑞哲®联合 CHOP 化疗治疗的两种给 药方案探索，均展现出令人鼓舞的抗肿瘤疗效和可控的安全性，有 ...

Core Viewpoint - The company, DIZH Medical (688192.SH), announced significant advancements in two globally innovative drugs at the 67th American Society of Hematology (ASH) conference, focusing on treatments for T-cell and B-cell lymphomas [1] Group 1: Drug Developments - The high-selectivity JAK1 inhibitor, Golixtin (generic name: Golixtin capsules), has made multiple new progressions in the field of T-cell lymphoma [1] - The non-covalent LYN/BTK dual-target inhibitor, birelentinib (DZD8586), has presented the latest clinical data for the treatment of B-cell lymphoma [1]

Core Insights - The company announced the latest research results of two globally innovative drugs at the 67th American Society of Hematology (ASH) conference, highlighting advancements in T-cell lymphoma and B-cell lymphoma treatments [1] Group 1: Drug Development - The high-selective JAK1 inhibitor, Golixtin (generic name: Golixtin capsules), has made significant progress in the field of T-cell lymphoma [1] - The non-covalent LYN/BTK dual-target inhibitor, birelentinib (DZD8586), has shown promising clinical data in the treatment of B-cell lymphoma [1] Group 2: Clinical Trial Results - In the Phase III recommended dose (RP3D) of 50mg, the overall response rate (ORR) was 84.2% [1] - Tumor remission was observed in patients who had previously received BTK inhibitors, Bcl-2 inhibitors, or BTK degraders, including those with classic BTK resistance mutations (C481X) or other BTK mutations [1] - The anti-tumor efficacy was durable, and safety was good, with no new safety issues reported during the follow-up period [1]

Core Viewpoint - The company DiZhe Pharmaceutical (688192) announced significant advancements in two innovative drugs at the 67th American Society of Hematology (ASH) conference, focusing on treatments for T-cell and B-cell lymphomas [1] Group 1: Drug Developments - The high-selectivity JAK1 inhibitor, Goli Siti Ni (generic name: Golisitini capsules), has made multiple new progressions in the field of T-cell lymphoma [1] - The non-covalent LYN/BTK dual-target inhibitor, birelentinib (DZD8586), has presented the latest clinical data for the treatment of B-cell lymphoma [1]

Core Insights - The company, Dizhi Pharmaceutical, announced the latest research results of its two globally innovative drugs at the 67th American Society of Hematology (ASH) conference, highlighting advancements in T-cell lymphoma and B-cell lymphoma treatments [1] Group 1: Drug Development - The high-selective JAK1 inhibitor, Golixtin (generic name: Golixtin capsules), has made significant progress in the T-cell lymphoma field [1] - The non-covalent LYN/BTK dual-target inhibitor, birelentinib (DZD8586), has shown promising clinical data in the treatment of B-cell lymphoma [1] Group 2: Clinical Trial Results - In the Phase III recommended dose (RP3D) of 50mg, the overall response rate (ORR) was 84.2% [1] - Tumor remission was observed in patients previously treated with BTK inhibitors, Bcl-2 inhibitors, or BTK degraders, including those with classic BTK resistance mutations (C481X) or other BTK mutations [1] - The anti-tumor efficacy was durable, and safety was good, with no new safety issues reported during the follow-up period [1]

进一步统计，近3个月内该股累计发生3笔大宗交易，合计成交金额为2658.21万元。 | 成交量 | 成交金额 | 成交价 | 相对当日收盘 | | | | --- | --- | --- | --- | --- | --- | | （万 | （万元） | 格 | 折溢价（%） | 买方营业部 | 卖方营业部 | | 股） | | （元） | | | | | 30.57 | 1778.58 | 58.19 | -7.84 | 国投证券股份有限公司武 | 国投证券股份有限公司武 | | | | | | 汉青年路证券营业部 | 汉青年路证券营业部 | （文章来源：证券时报网） 证券时报·数据宝统计显示，迪哲医药-U今日收盘价为63.14元，上涨3.56%，日换手率为0.62%，成交额 为1.78亿元，全天主力资金净流出440.31万元，近5日该股累计下跌3.03%，近5日资金合计净流出827.41 万元。 两融数据显示，该股最新融资余额为1.91亿元，近5日增加2532.91万元，增幅为15.25%。（数据宝） 12月4日迪哲医药-U大宗交易一览 迪哲医药-U12月4日大宗交易平台出现一笔成交，成交量30.57万股 ...

| of the Call "a voltar children it form I hand" | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | | 交易日期 | 证券简称 | 证券代码 | 成交价(元) 成交金额(万元) 成交量( * ) 买入营业部 | | | 卖出营业部 | 是否为专场 | | 025-12-04 | 迪普医药 | 688192 | 58.19 1778.58 | 30.57 | 容易度多能商家感 | 型用甚至修成员感 | KO | 12月4日，迪哲医药大宗交易成交30.57万股，成交额1778.58万元，占当日总成交额的9.1%，成交价 58.19元，较市场收盘价63.14元折价7.84%。 ...

Core Insights - The pharmaceutical sector is experiencing a rise, with the Shanghai Stock Exchange Sci-Tech Innovation Board Biomedicine Index increasing by 1.03% as of December 4, 2025, with notable gains from companies like Zai Lab (up 4.47%) and Rongchang Bio (up 4.14%) [1] Industry Overview - The pharmaceutical industry has undergone eleven rounds of national drug centralized procurement and multiple rounds of medical insurance negotiations, leading to an inevitable decline in the generic drug sector, which impacts the overall pharmaceutical industry [1] - From January to September 2025, the pharmaceutical manufacturing industry's revenue remained relatively stable, but the outlook for generic drugs is bleak, indicating a need for innovative drugs to drive future growth [1] Investment Perspective - According to Everbright Securities, future investments in the pharmaceutical sector should focus on the clinical value of drugs, addressing clinical needs of patients, as both domestic medical insurance policies and global expansion strategies increasingly emphasize clinical value [1] - The innovative drug industry chain and innovative medical devices are viewed positively based on the clinical value framework [1] Market Data - As of November 28, 2025, the top ten weighted stocks in the Shanghai Stock Exchange Sci-Tech Innovation Board Biomedicine Index include companies like United Imaging Healthcare and BeiGene, collectively accounting for 49.75% of the index [1]

Core Insights - The A-share private placement market is experiencing significant participation from public funds in 2025, with 33 fund companies involved and a total allocation amounting to 17.3 billion yuan, representing a 140% increase compared to the entire year of 2024 [1][5][8] Group 1: Market Participation - Public funds have shown a marked increase in enthusiasm for private placements, with a total allocation of 17.3 billion yuan in 2025, up from 7.2 billion yuan in 2024, indicating a growth of over 100 billion yuan [5][6] - Leading public fund companies include E Fund with 3.687 billion yuan, followed by GF Fund, Fortune Fund, and China Universal Fund with allocations of 2.288 billion yuan, 1.529 billion yuan, and 1.463 billion yuan respectively [5][6] Group 2: Investment Focus - The investment focus of public funds is heavily concentrated in hard technology sectors, particularly in semiconductors, artificial intelligence, and innovative pharmaceuticals, reflecting a strong alignment with the ongoing "technology bull" market [6][8] - Notable allocations in the electronics sector reached 7.45 billion yuan, while the biopharmaceutical sector saw allocations of 5.6 billion yuan, targeting companies like Cambricon, Chipone, and innovative drug firms [6][8] Group 3: Market Drivers - The resurgence of private placements is driven by three main factors: policy incentives, a safety margin due to discount pricing, and significant profit potential observed by participating public funds [8] - The current trend shows increased participation, improved returns, and a strong focus on technology and high-end manufacturing sectors, with expectations for continued growth in public fund involvement in private placements [8]

Core Insights - The A-share private placement market is experiencing significant growth, with public funds participating deeply in 2025, leading to a total allocation of 17.3 billion yuan, a 140% increase compared to the entire year of 2024 [1][3][4] Group 1: Market Participation - A total of 33 public fund companies have participated in private placements, with the leading fund, E Fund, securing 3.687 billion yuan [3][4] - Other notable funds include GF Fund, Fortune Fund, and China Universal Fund, with allocations of 2.288 billion yuan, 1.529 billion yuan, and 1.463 billion yuan respectively [3][4] - The trend shows a competitive landscape where larger funds dominate, but smaller funds are also actively participating [3][4] Group 2: Investment Focus - Public funds are primarily focusing on hard technology sectors, particularly semiconductors, artificial intelligence, and innovative pharmaceuticals, reflecting a strong alignment with industry trends [4][5] - The electronic industry received 7.45 billion yuan in allocations, while the biopharmaceutical sector saw 5.6 billion yuan, with key companies like Cambricon, Chipone, and Bairi Tianheng being major targets [4][5] Group 3: Market Drivers - The resurgence in private placements is driven by three main factors: policy incentives, built-in discount safety, and significant profit potential [7] - The favorable policy environment encourages capital market support for the real economy, especially in technology sectors [7] - The overall performance of public funds in private placements has been strong, further motivating institutional participation [7]